In this trial, datopotamab deruxtecan, an anti-TROP2 ADC, was used to treat patients with NSCLC and targetable genomic alterations (including EGFR mutation and ALK and RET fusions) who had progressed to prior treatment options (82% of patients had received ≥3 lines). This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.